Synthesis of 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents.

@article{Chou2010SynthesisO1,
  title={Synthesis of 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents.},
  author={Li-Chen Chou and Li‐Jiau Huang and M. Hsu and Meitong Fang and Jai-Sing Yang and Shi-Hong Zhuang and Hui-Yi Lin and F. Lee and C. Teng and S. Kuo},
  journal={European journal of medicinal chemistry},
  year={2010},
  volume={45 4},
  pages={
          1395-402
        }
}
As part of our continuing search for potential anticancer drug candidates among YC-1 analogs, 1, 3-disubstituted selenolo[3,2-c]pyrazole derivatives were synthesized and evaluated for their cytotoxicity against NCI-H226 non-small cell lung cancer and A-498 renal cancer cell lines. Significant cytotoxicity was observed in 3-(5-hydroxymethyl-2-furyl) derivatives (2, 33, 36 and 37). Among them, compound 2 was found to have the most potent activity. The mode of action of compound 2 seems to differ… Expand
Synthesis and anticancer activity of 2,4-disubstituted furo[3,2-b]indole derivatives.
TLDR
The COMPARE analysis results suggest that the 10a fingerprint is similar to that of NSC-754549, which is an isostere of YC-1, and should be further developed as a new drug candidate for treating renal cancer. Expand
Synthesis of ester and amide derivatives of 1-phenyl-3-(thiophen-3-yl)-1H-pyrazole-4-carboxylic acid and study of their anticancer activity
A series of novel thiophene containing 1,3-diarylpyrazole derivatives were synthesized and the structures were determined by IR, 1H-NMR, and HRMS analysis. The anticancer activity of the titleExpand
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
TLDR
It is observed that 9-(2-methoxybenzyl)-β-carboline-3-carboxylic acid inhibited the growth of HL-60 cells by inducing apoptosis, with a half maximal inhibitory concentration of 4.0 μM, indicating that β- carboline derivatives can be used as lead compounds for developing novel antitumor agents. Expand
Synthesis, crystal structure and biological evaluation of novel 2-(5-(hydroxymethyl)-3-phenyl-1H-pyrazol-1-yl)-1-phenylethanol derivatives.
TLDR
Preliminary biological evaluation showed that compounds 4d and 4e could suppress A549 lung cancer cell growth through cell cycle arrest and autophagy. Expand
A convenient synthesis, reactions and biological evaluation of novel pyrazolo[3,4-b]selenolo[3,2-e]pyrazine heterocycles as potential anticancer and antimicrobial agents
A novel series of 5-amino-6-substituted-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]selenolo[3,2-e]pyrazines (3a–e) was synthesized by the reaction of the chloro pyrazolo[3,4-b]pyrazine carbonitrile 1 withExpand
A convenient synthesis, reactions and biological studies of some novel selenolo[2,3-c]pyrazole compounds as antimicrobial and anti-inflammatory agents
Abstract5-Chloro-3-methyl-1-phenylpyrazole-4-carbonitrile 3 was reacted with selenium in the presence of sodium borohydride and chloroacetamide to afford selanyl acetamide 5, which underwentExpand
SYNTHESIS OF QUINOLINYL-OXADIAZOLE AS A POTENT ANTIBACTERIAL AGENT AND SA-FABI INHIBITOR
Objective: Microbial resistance to currently marketed drugs is a serious problem worldwide and there is a vital need to develop novel antibiotics. Enoyl-ACP reductase (FabI) is essential for fattyExpand
Microwave-assisted synthesis, crystal structure of pyrazolo[1,5-a]pyrazin-4(5H)-ones and their selective effects on lung cancer cells.
TLDR
A series of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives with hydrophilic group was synthesized under general heating condition and microwave-assisted condition showing that some compounds could inhibit the growth of A549, H322 and H1299 cells in dosage dependent manners. Expand
Selective synthesis of novel 2-imino-1,3-selenazolidin-4-ones and 2-amino-1,3,4-selenadiazin-5-ones from isoselenocyanates
Abstract An efficient and regioselective synthesis of 2-imino-1,3-selenazolidin-4-ones and 2-amino-1,3,4-selenadiazin-5-ones was achieved via one-pot reaction of isoselenocyanates, hydrazines, andExpand
Synthesis and antiproliferative evaluation of novel 1,2,4-triazole derivatives incorporating benzisoselenazolone scaffold.
TLDR
The pharmacological results suggest that the substituent groups are vital for improving the potency and selectivity of this class of compounds. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 11 REFERENCES
Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents.
TLDR
Through investigation of action mechanism, 1-benzyl-3-(substituted aryl)-5-methylfuro[3,2-c]pyrazole is identified here as a new lead compound of cell differentiating agent and apoptosis inducer for further development of new anti-leukemia agents. Expand
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
TLDR
1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (28, YC-1) was selected as the lead compound for systemic structural modification and compound 58 was found to be a selective and potent inhibitor of protease-activated receptor type 4 (PAR4)-dependent platelet activation. Expand
1-(3,4-dimethoxyphenyl)-3,5-dodecenedione (I6) induces G1 arrest and apoptosis in human promyelocytic leukemia HL-60 cells.
TLDR
I6 is a potent anti-HL-60 drug and possess a significant action on cell cycle before commitment for apoptosis occurrence, suggesting that the Bcl-2 expression decrease and caspase-3 activation may be the plausible mechanism by which I6 induced apoptosis. Expand
YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors in Vitro and Angiogenesis in Vivo Models
  • S. Pan, J. Guh, +7 authors C. Teng
  • Biology, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
  • 2005
TLDR
YC-1 administered orally in doses of 1 to 100 mg/kg/day inhibited VEGF- and bFGF-induced neovascularization in a dose-dependent manner over 7 days indicate that YC- 1 has antiangiogenic activity at very low doses. Expand
Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226.
TLDR
Findings suggest a mechanism of cytotoxic action of YC-1 and indicate that YC -1 may be a promising chemotherapy agent against lung cancer. Expand
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
TLDR
The inhibition of HIF-1 alpha activity in tumors from YC-1-treated mice is associated with blocked angiogenesis and an inhibition of tumor growth and has the potential to become the first antiangiogenic anticancer agent to target Hif-1alpha. Expand
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
TLDR
A pilot-scale, in vitro, anticancer drug screen utilizing a panel of 60 human tumor cell lines organized into subpanels representing leukemia, melanoma, and cancers of the lung, colon, kidney, ovary, and central nervous system is described. Expand
YC-1, a novel activator of platelet guanylate cyclase.
TLDR
The data indicate that YC-1 is a direct soluble guanylate cyclase activator in rabbit platelets and may also possess antithrombotic potential in vivo. Expand
Mechanism of YC-1-induced activation of soluble guanylyl cyclase.
TLDR
Results indicate that YC-1 increases the maximal catalytic rate and sensitizes the enzyme toward its gaseous activators by binding to an allosteric site on sGC molecules, thereby reducing the ligand dissociation rate from the heme group. Expand
YC‐1 inhibited human platelet aggregation through NO‐independent activation of soluble guanylate cyclase
TLDR
The results would suggest that YC‐1 activates sGC of human platelets by a NO‐independent mechanism, and exerts its antiplatelet effects through the sGC/cyclic GMP pathway. Expand
...
1
2
...